Can I use laser/RF if I’m on HRT or local oestrogen?

Detailed Medical Explanation

Can I use laser/RF if I’m on HRT or local oestrogen? In principle, yes. These approaches address different contributors to symptoms often labelled “vaginal laxity”. Systemic HRT (tablets, patches, gels) and local vaginal oestrogen act on the epithelium and submucosa to improve hydration, elasticity and pH balance in genitourinary syndrome of menopause (GSM). Vaginal lasers (e.g., fractional CO₂ or erbium) and radiofrequency (RF) deliver controlled energy to the vaginal wall aiming to stimulate collagen remodelling and surface comfort. Using them together is typically acceptable after a proper assessment, with the understanding that devices are adjuncts rather than a substitute for pelvic floor rehabilitation or GSM care.

Why foundations still matter. If the key limiter is pelvic floor endurance/coordination, device sessions will not replace training. A supervised programme (activation, long holds, quick squeezes, “the knack”) remains first-line. If the main problem is dryness/sting from GSM, regular vaginal moisturiser plus a generous, compatible lubricant and, if acceptable, local vaginal oestrogen often resolve the “loose yet sore” paradox without procedures. Only if targeted, entry-focused concerns persist (e.g., reproducible air-trapping, early-penetration discomfort) should devices be discussed as an optional next layer.

How we combine therapies safely. We normally continue local oestrogen on its existing schedule before, during and after device sessions unless your prescribing clinician advises otherwise. This supports epithelial resilience and comfort around the time of treatment. A practical tip is to apply a fingertip of cream at the vestibule and posterior fourchette (as well as internally) if these are your sorest points. If you’re on systemic HRT, there’s no routine need to pause it for laser/RF; what matters is screening for red flags and setting realistic goals.

Sequencing and expectations. A typical plan—if a device is chosen after foundations—uses 2–3 sessions spaced 4–8 weeks apart, with a review 6–12 weeks after the final session. Hormone therapy continues on its usual schedule throughout. Track real-life outcomes: fewer micro-tears, calmer sting, less air-trapping, steadier tampon retention, easier initial penetration. If progress is modest, it’s reasonable to stop rather than escalate.

NICE, NHS and safety context. UK guidance prioritises conservative measures and local therapies for GSM. Energy-based intimate treatments remain under special arrangements (governance, consent, audit) because evidence is limited and heterogeneous; that does not prohibit combination with HRT, but it does mean selection and follow-up are important. Devices should be used within their intended purpose with appropriate UKCA/CE marking; unexpected effects should be reported via UK safety channels.

Practical pathway & booking. If you’re weighing up a combination approach, it helps to revisit the stepwise plan—what comes first, what we add next, and how we review changes over time—under how treatment steps are sequenced. If you are budgeting or comparing packages, see treatment prices for what’s included.

When to pause and seek review. Defer device sessions (and sometimes adjust local therapy) if you have active BV/thrush/UTI, malodorous discharge, fever, new post-menopausal bleeding, recent pelvic/perineal surgery without clearance, or poorly controlled pelvic pain. Suspected prolapse beyond the introitus or levator injury warrants uro-gynaecology input first. If breast cancer is part of your history and you’re on adjuvant therapy, coordinate any changes to local oestrogen with your oncology team before undertaking additional procedures.